LTFU for all cell and gene therapy studies - LOCUS

Study identifier:D9341C00001

ClinicalTrials.gov identifier:NCT06194461

EudraCT identifier:N/A

CTIS identifier:N/A

Will Be Recruiting

Official Title

A LOng-term Follow-up Master Protocol for Participants who Received Cell or Gene Therapies in Other AstraZeneca StUdieS (LOCUS)

Medical condition

Hepatocellular Carcinoma

Phase

Phase 1/2

Healthy volunteers

No

Study drug

-

Sex

All

Estimated Enrollment

30

Study type

Observational

Age

18 Years - 130 Years

Date

Study Start Date: 21 Feb 2024
Estimated Primary Completion Date: 29 Nov 2041
Estimated Study Completion Date: 29 Nov 2041

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Jan 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria